ABBOTT LABORATORIES Unrecognized Tax Benefits, Period Increase (Decrease)
ABBOTT LABORATORIES (ABT) reported Unrecognized Tax Benefits, Period Increase (Decrease) of $1.30 billion for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-16.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease · last filed 2024-02-16
- ABBOTT LABORATORIES unrecognized tax benefits, period increase (decrease) for the quarter ending 2017-03-31 was -$33.00M.
- ABBOTT LABORATORIES unrecognized tax benefits, period increase (decrease) for the quarter ending 2016-09-30 was -$102.00M.
- ABBOTT LABORATORIES unrecognized tax benefits, period increase (decrease) for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- ABBOTT LABORATORIES unrecognized tax benefits, period increase (decrease) for the quarter ending 2016-03-31 was -$444.00M, a 2875.00% decline year-over-year.
- ABBOTT LABORATORIES unrecognized tax benefits, period increase (decrease) for fiscal 2023 was $1.30B.
| Period end | Unrecognized Tax Benefits, Period Increase (Decrease) 3 month | Unrecognized Tax Benefits, Period Increase (Decrease) 6 month | Unrecognized Tax Benefits, Period Increase (Decrease) 9 month | Unrecognized Tax Benefits, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.30B 10-K · filed 2024-02-16 | |||
| 2017-09-30 | -$80.00M 10-Q · filed 2017-11-02 | |||
| 2017-03-31 | -$33.00M 10-Q · filed 2018-05-02 | |||
| 2016-09-30 | -$102.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$102.00M derived: sum of 2 quarters · filed 2017-11-02 | -$546.00M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$444.00M 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | -$444.00M 10-Q · filed 2017-05-03 | |||
| 2015-09-30 | -$19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $16.00M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $35.00M 10-Q · filed 2015-08-04 | ||
| 2015-03-31 | $16.00M 10-Q · filed 2015-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |